Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Remdesivir for the Treatment of Covid-19 - Final Report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Compassionate Use of Remdesivir in Covid-19

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. A More COMPLETE Picture of Revascularization in STEMI

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  1. Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hypertension, cardiovascular disease and cause of death in Danish living kidney donors: matched cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • John J V McMurray
  • Scott D Solomon
  • Silvio E Inzucchi
  • Lars Køber
  • Mikhail N Kosiborod
  • Felipe A Martinez
  • Piotr Ponikowski
  • Marc S Sabatine
  • Inder S Anand
  • Jan Bělohlávek
  • Michael Böhm
  • Chern-En Chiang
  • Vijay K Chopra
  • Rudolf A de Boer
  • Akshay S Desai
  • Mirta Diez
  • Jaroslaw Drozdz
  • Andrej Dukát
  • Junbo Ge
  • Jonathan G Howlett
  • Tzvetana Katova
  • Masafumi Kitakaze
  • Charlotta E A Ljungman
  • Béla Merkely
  • Jose C Nicolau
  • Eileen O'Meara
  • Mark C Petrie
  • Pham N Vinh
  • Morten Schou
  • Sergey Tereshchenko
  • Subodh Verma
  • Claes Held
  • David L DeMets
  • Kieran F Docherty
  • Pardeep S Jhund
  • Olof Bengtsson
  • Mikaela Sjöstrand
  • Anna-Maria Langkilde
  • DAPA-HF Trial Committees and Investigators
Vis graf over relationer

BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.

METHODS: In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.

RESULTS: Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups.

CONCLUSIONS: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind381
Udgave nummer21
Sider (fra-til)1995-2008
ISSN0028-4793
DOI
StatusUdgivet - 21 nov. 2019

Bibliografisk note

Copyright © 2019 Massachusetts Medical Society.

ID: 58252985